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Summary
Background: We compared the efﬁcacy of once-daily treatment with nifedipine CR 40mg (NR)
and twice-daily treatment with benidipine 4mg (BD) in patients with coronary spastic angina
(CSA) registered in 3 cardiovascular institutes in Tokyo.
Methods and results: CSA was diagnosed by an ischemic ST change during Holter ECG monitoring
or drug-induced test. Thirty patients were randomly allocated to either NR or BD group. The
number of symptomatic attacks and the total frequency of short-acting nitrates were exam-
ined based on the data in diaries written by patients. There were no signiﬁcant differences in
the baseline characteristics between the two groups. The median number (25—75% quartile) of
attacks per week was signiﬁcantly decreased in NR group, i.e., 1.0 (0.8—2.0) at baseline, 0.0
(0.0—1.0) after 4 weeks of treatment, and 0.0 (0.0—0.0) after 8 weeks of treatment (P = 0.0093,
P = 0.0002, Wilcoxon’s rank-sum test). No signiﬁcant decrease was observed in BD, i.e. 1.0
(0.5—2.0) at baseline, 1.3 (0.0—3.0) after 4 weeks, and 0.0 (0.0—1.0) after 8 weeks. The
number of attacks was fewer in NR than in BD group (P = 0.074, P = 0.015, U-test for difference).
∗ Corresponding author. Tel.: +81 3 3408 2151; fax: +81 3 3401 0469.
E-mail address: oikawa@cvi.or.jp (Y. Oikawa).
914-5087/$ — see front matter © 2009 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.jjcc.2009.11.005
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Conclusion: Once-daily treatment with NR 40mg was more effective than twice-daily treatment
CSA attacks.
ardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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state within 4 weeks after the start of administration
and 8 weeks was set because sufﬁcient effects should be
obtained.with BD in the prevention of
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Introduction
Coronary vasospasms are deeply involved in the etiol-
ogy and prognosis of ischemic heart disease including
not only variant angina pectoris but also acute myocar-
dial infarction, arrhythmia, and sudden cardiac death in
Japanese [1—3]. Racial differences in the gene related to
coronary vasospasms have been noted in relation to the
high frequency of such vasospasms in Japanese patients
[4—6]. Problems have been caused by coronary vasospasms
after coronary artery intervention [7], especially coronary
vasospasms occurring after implantation of drug-eluting
stents [8,9] and such problems will have to be solved in
the future. It has been known for some time that calcium-
channel blockers (Ca channel blockers) including nifedipine
and diltiazem are effective in the treatment of variant
angina pectoris associated with coronary vasospasms [10]. In
the Guidelines for Diagnosis and Treatment of Patients with
Coronary Spastic Angina published in 2008 [11], Ca channel
blockers are recommended as Class I treatment (evaluation
method, treatment useful, efﬁcacy can be proven or there
is widespread agreement). However, it has been pointed out
that there are Ca channel blockers that are not covered by
health insurance to treat angina pectoris or coronary spastic
angina, and that differences in the prognostic improve-
ment action of various Ca blockers are possible according
to the most recently published cohort research [12—17].
However, since almost no prospective clinical studies on
therapeutic effects of different Ca channel blockers have
been published to date because of the characteristic patho-
physiology of coronary spastic angina pectoris, objective
evidence has not been obtained at present. Drugs to treat
coronary spastic angina pectoris must show early inhibitory
effects on attacks, and in long-term administration, must
have excellent improvement effects on prognosis. In the
present randomized non-blinded study, we examined the
inhibitory effects on angina attacks of short-term treatment
with long-acting Ca channel blockers in patients with coro-
nary spastic angina. The test drugs were nifedipine in the
form of nifedipine CR tablets specially designed for use once
daily [18], which have been supplied clinically in Japan since
1976 and are known to be especially effective against variant
angina, and the Ca channel blocker benidipine used twice
daily and suggested to improve prognosis in a recent cohort
study [17].
MethodsStudy population
The patients were angina pectoris outpatients registered
in three facilities specializing in cardiovascular medicine
in Tokyo from January 2007 to December 2008. The angina
attacks were in the early morning or at rest as a rule.Based
t
t
o
pn the diagnostic criteria in our facility, patients who
et the following three requirements were considered as
aving coronary spastic angina: (1) ischemic ST segment
hanges observed in Holter electrocardiogram (ECG) on
ppearance of chest pains at rest; (2) coronary vasospasms
nduced in selective acetylcholine or ergonovine provoca-
ion tests and ischemic changes of 1mm or more in ECG
19—21]; and (3) coronary spastic angina strongly suspected
y the attending physicians. Patients with concomitant
rganic stenosis of 50% or more and patients indicated for
evascularization surgery were excluded from this study.
he exclusion criteria speciﬁed patients with a myocardial
nfarction within one month, diabetic patients with poorly
ontrolled blood glucose, patients with severe hypertension
≥180/≥110mmHg), patients who could not tolerate dihy-
ropyridine calcium-channel blockers, and other patients
udged by the attending physicians to be inappropriate
s participants in the study. Thirty patients complying
ith these criteria were registered in the study and
nformed consent in writing was obtained from each sub-
ect.
ethod of inducing coronary vasospasms
oronary vasospasms were induced by intracoronary injec-
ion of acetylcholine or ergonovine after catheterization in
he morning [19—21]. Coronary spasm positive ﬁndings in
oronary arteriography in the induction test using the drugs
ere deﬁned as ‘‘signs of myocardial ischemia [transient
omplete or incomplete obstruction (>90% stenosis) associ-
ted with anginal pain and ischemic ECG changes].’’
tudy protocol
atients with coronary spastic angina complying with the
nclusion criteria were allocated at random to two groups by
he envelope method (benidipine group: twice a day at 4mg
ach time after the morning and evening meal or nifedip-
ne CR group: once a day at 40mg each time after the
vening meal). The treatment period during development
f anti-angina drugs is set at within 4 weeks [22,23], but
reatment with our test drugs was set at 8 weeks in keep-
ng with the outpatient treatment schedule. In reference
o the guidelines for the clinical evaluation of anti-anginal
rugs, both drugs were assumed to have reached a steadyConcomitant use of coronary vasodilators other than
he test drugs was basically prohibited during the allotted
reatment period. When adverse drug reactions occurred
r effects were inadequate with the allotted drug, it was
ossible to change the test drug or add other drugs at the
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iscretion of the attending physician. Such patients were
andled as dropouts.
The tests performed at baseline and after 4 and 8 weeks
f treatment with the test drug included outpatient blood
ressure and heart rate measurements. Patients were given
otebook-type symptom diaries and instructed to record
aily reports on their physical condition. When attacks of
hest pain occurred, the day, times, subjective symptoms,
everity, and use of fast-acting nitrates were recorded and
he patients were instructed to bring them the next time
hey came to the outpatient clinic. The periods of diary
ntries for the patients were for 4 weeks before receiving
he test drugs, and for 4 weeks and 8 weeks after adminis-
ration of the test drugs for a total of 12 weeks as a rule.
he number of angina attacks and doses of rapid-acting
itroglycerine were examined at baseline and after 4 and
weeks of treatment using a symptom diary. Holter ECGs
ere used at baseline and after 8 weeks of treatment to
etect ischemic ST segment changes.
When patients complained of worsening of complica-
ions with new symptoms appearing during treatment and
ausality with the test drug could not be ruled out, such
vents were considered as adverse drug reactions. Efﬁcacy
as evaluated in the following ﬁve grades by the attending
hysicians based on the subjective symptoms and objec-
ive signs of the patients: (1) marked improvement (attacks
ompletely disappeared); (2) improvement (decreased by
0% or more); (3) slight improvement (decreased around
5%); (4) unchanged; and (5) worse (number of attacks
ncreased).
The discontinuation criterion for the study was in cases
here it was judged to be difﬁcult to continue with the
est drug allocated by the attending physicians because
f patient’s complaint, the patient shows new concomi-
ant symptoms, abnormal variations in laboratory ﬁndings,
orsening of symptoms or serious comorbid diseases. If
reatment with the allocated test drug was discontinued,
he time of discontinuation and reason were recorded
n the survey form, and the efﬁcacy and safety evalu-
tion was performed at that time. When the patient’s
onsent was obtained after the study had been discontin-
ed, the drug was switched to the other test drug and
p
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Figure 1 Flow of the patiY. Oikawa et al.
bservations continued at the discretion of the attending
hysician.
tatistical analysis
he main objective of this research was a comparative study
f the inhibitory effects of once daily administration of
ifedipine CR and twice-daily benidipine for 8 weeks on the
umber of attacks in patients with coronary spastic angina
ndergoing outpatient treatment. The primary endpoint in
his study was the decrease in the number of attacks based
n patient complaints. Results of randomized comparative
linical studies of the inhibitory effects of Ca channel block-
rs of coronary spastic angina (variant angina) appeared
poradically during new drug development [22—24], and
hey were not conducted under actual treatment conditions.
asue et al. [24] performed a comparative study on 8mg/day
nd 16mg/day of benidipine in 27 patients at the time of
evelopment of benidipine and found that the number of
ttacks was reduced by 57% at 8mg/day, but the efﬁcacy
as less than at 16mg/day. When nifedipine CR was under
evelopment, it was reported that the number of attacks
as reduced by 96% in a study on 31 patients given nifedip-
ne CR 40—60mg/day with nisoldipine at 10—15mg/day as
he control drug [23]. Using these results for reference, the
ifference in inhibition of attacks was assumed to be 40%.
n consideration of the registration criteria and the condi-
ions of the outpatients with angina pectoris in this study,
he mean number of attacks was set at 3.0/week (stan-
ard deviation 2.0) and its was assumed that a difference
f 1.2± 0.8 times/week would be obtained between the 2
roups. When the two-sided level of signiﬁcance was set at
% with a power of 95%, 13 subjects per group would be
equired. With a dropout rate of 15%, the targeted number
f patients in this study was set at 30.
In the statistical analysis of the data obtained, theaired Wilcoxon’s test was used for number of attacks and
hanges in the dose of rapid-acting nitrate agents. The
-test was used for differences in comparisons of these
tems between the test drug groups. Measured values were
xpressed as mean± standard deviation (SD) or median val-
ents through the trial.
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ues (ﬁrst quartile—third quartile). Blood pressure and heart
rate were expressed as mean± SD, and Student’s t-test was
used for statistical analysis. In intergroup comparisons of
efﬁcacy, ‘‘slightly effective’’ or better was considered as
effective and the chi-squared test was used. In all tests,
P < 0.05 was taken as a signiﬁcant difference.
Results
Characteristics of study patients
The patient ﬂowchart is shown in Fig. 1. Thirty patients were
included in this study. Among the patients allocated benidip-
ine, one patient discontinued administration of benidipine
because the patient complained of ≥40 attacks/week on
day 11 after allocation of the drug, and the medication was
changed to nifedipine CR. One patient treated with nifedip-
ine CR discontinued administration because an excessive
drop in blood pressure occurred immediately after initia-
tion of treatment and was switched to benidipine. These
two patients were excluded as protocol violations and 28
patients (14 in the benidipine group and 14 in the nifedip-
ine CR group) were subject to the efﬁcacy evaluation. The
clinical characteristics of the patients are shown in Table 1.
Among the patients subject to evaluation, 79% (22/28) had
untreated coronary spastic angina and coronary vasospasms
were diagnosed in 89% of them (25/28) by drug loading
tests. No differences were found in coronary risk factors,
age, blood pressure, smoking habit, heart rate, BMI, sever-
ity of attacks, and concomitant use of drugs to treat lipid
abnormalities or antiplatelet drugs between the groups. In
observations immediately before treatment with the test
drug, the number of angina attacks per week (mean± SD)
was 1.41± 1.07 in the benidipine group and 3.51± 7.70 in
c
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Figure 2 Changes in the number of attacks (nifed241
he nifedipine CR group, and there was no signiﬁcant differ-
nce between the groups.
umber of angina attacks
ig. 2 shows the number of attacks of chest pain in the
ymptom diaries. Among 14 patients in the nifedipine CR
roup, eight patients had no attacks within 4 weeks of
tart of treatment and only two of the 14 patients still
ad attacks after 4 weeks. However, among the 14 patients
n the benidipine group, four had had no attacks within 4
eeks of start of treatment, while four patients discon-
inued use of benidipine because of an increase in the
umber of attacks. As a result, only 10 patients were
bserved for a period of 8 weeks. In six of these 10
atients, the attacks had disappeared in the evaluation after
weeks. When the changes in the number of attacks were
nalyzed statistically, 3.5± 7.7, 1.0 (0.8—2.0) times/week
mean± SD, median value (ﬁrst quartile—third quartile)
t baseline had decreased to 0.7± 1.3, 0.0 (0.0—1.0)
imes/week after 4 weeks (P = 0.0093, Wilcoxon’s rank-
um test), and 0.1± 0.4, 0.0 (0.0—0.0) times/week after 8
eeks (P = 0.0002, Wilcoxon’s rank-sum test) in the nifedip-
ne CR group. In the benidipine group, the ﬁgures were
.4± 1.1, 1.0 (0.5—2.0) times/week at baseline, 2.3± 3.7,
.3 (0.0—3.0) times/week after 4 weeks, and 0.6± 0.8,
.0 (0.0—1.0) times/week after 8 weeks. No signiﬁcant
ecreases were observed throughout the treatment period
n the benidipine group. When the number of attacks were
ompared between the two groups, the nifedipine CR group
ended to show a decrease after 4 weeks when com-
ared with the benidipine group (P = 0.074, U-test). After
weeks, a signiﬁcant decrease was observed (P = 0.015, U-
est) (Fig. 3) (Table 2).
ipine CR 40mg/day vs. benidipine 8mg/day).
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Table 1 Patient background.
Nifedipine CR (n = 14) Benidipine (n = 14) P-value
Gender (n, male/female) 14 (9/5) 14 (13/1) N.S.
Age (mean± SD) 64.6± 10.8 61.2± 14.0 N.S.
Basis of diagnosis
Holter ECG 0 0
Drug-induced test 13 12 N.S.
Other 1 2 N.S.
Systolic blood pressure (mmHg, mean± SD) 128± 17 127± 18 N.S.
Diastolic blood pressure (mmHg, mean± SD) 75± 11 71± 10 N.S.
Heart rate (min, mean± SD) 73± 14 72± 19 N.S.
History of MI (n) 0 0
Smoking habit (n) 6 10 N.S.
BMI (mean± SD) 23.5± 3.0 23.4± 2.5 N.S.
Complications (n)
None 6 6 N.S.
Present 8 8 N.S.
Hypertension 4 5 N.S.
Diabetes mellitus 0 1 N.S.
Lipid abnormality 3 7 N.S.
Obesity 2 1 N.S.
Other 1 2 N.S.
Prior medication (n)
No medication for angina 10 12 N.S.
Previous medication for angina 4 2 N.S.
Diltiazem 3 0 N.S.
Amlodipine 0 1 N.S.
Nitrates 2 2 N.S.
-Blocker 1 0 N.S.
Concomitant drugs (n)
Statins 2 4 N.S.
Antiplatelet drug 2 3 N.S.
Number of attacks (times/week, mean± SD) 3.50± 7.70 1.41± 1.07 N.S.
Severity (n)
No attack 0 0
Mild 2 4 N.S.
Moderate 8 4 N.S.
Severe 5 8 N.S.
Frequency of short-acting nitrates (tablet/week, mean± SD) 0.43± 0.65 0.66± 1.12 N.S.
Average dose of study drug (/day) 40mg 8mg
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CECG, electrocardiogram; MI, myocardial infarction; BMI, body ma
apid-acting nitrates used
he dose of rapid-acting nitroglycerine based on the
ymptom diaries was 0.43± 0.65 tablets/week (mean± SD)
t baseline, 0.36± 0.82 tablets/week after 4 weeks and
.14± 0.36 tablets/week after 8 weeks in the nifedipine CR
roup. No signiﬁcant changes occurred at any time of treat-
ent. In the benidipine group, the ﬁgures were 0.66± 1.12
t baseline, 1.11± 2.77 after 4 weeks, and 0.25± 0.63 after
weeks. No signiﬁcant changes occurred throughout the
reatment period (Table 2).
With respect to Holter ECG ﬁndings, since ischemic ST-T
hange was not detected before and after treatment with
a
1
o
g
aex; N.S.: not signiﬁcant.
he study drug in either patient, ECG improvement rates
ere not evaluable (Table 2).
lood pressure and heart rate
hanges in the outpatient blood pressure in the nifedipine
R group were SBP 128± 17/DBP 75± 11mmHg (mean± SD)
t baseline, 128± 16/80± 16mmHg after 4 weeks, and
26± 12/77± 7mmHg after 8 weeks. No signiﬁcant changes
ccurred at any time of treatment. In the benidipine
roup, the ﬁgures were SBP 127± 18/DBP 71± 10mmHg
t baseline, 127± 16/76± 8mmHg after 4 weeks, and
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iFigure 3 Comparison of decrease in numbers of attack from
126± 8/76± 7mmHg after 8 weeks. No signiﬁcant changes
occurred (Fig. 4). The heart rate in the nifedipine CR
group was 72± 15 beats/min at baseline, 78± 10 beats/min
after 4 weeks, a slight increase, but after 8 weeks, it
was 73± 8 beats/min, and no signiﬁcant changes occurred
during treatment. In the benidipine group, the ﬁgures
were 71± 18 beats/min at baseline, 75± 8 beats/min after
4 weeks, and after 8 weeks it was 80± 11 beats/min, a slight
increase, but no signiﬁcant changes occurred, the same as
in the nifedipine CR group.
Smoking habit is an important factor for the onset of CSA
[25]. We provide CSA patients with lifestyle guidance such as
not smoking. As a result, although 6 patients in the nifedip-
ine CR group and 10 patients in the benidipine group had
been smokers before initiation of treatment, there were
no smokers in the two groups 8 weeks after treatment.
a
n
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Table 2 Main results and other risk factors after treatment.
Nifedipine CR (n = 14)
Baseline 8 weeks P-
Number of symptomatic
attacks by a symptom diary
(times/week)
3.50± 7.70 0.10± 0.40 0.
Frequency of short-acting
nitrates by a sympton diary
(tablets/week)
0.43± 0.65 0.14± 0.36 0.
Number of ischemic ST-T
change by Holter ECG
(times/day)
None None —
Smoking (+) (n) 6 0 0.
Total cholesterol (mg/dl) 201.2± 30.9 181.8± 27.4 0.
Serum creatinine (mg/dl) 0.8± 0.2 0.7± 0.1 0.
Mean± SD, n = number of patients.
P-value, paired Wilcoxon’s test or Fisher’s exact test vs baseline.
**P-value, U-test for difference or Fisher’s exact test, between 2 groupine between the 2 groups (nifedipine CR vs. benidipine).
he levels of total cholesterol and serum creatinine were
imilar between the two groups, showing no signiﬁcant
hanges after treatment (Table 2).
fﬁcacy rate
ig. 5 shows a comparison of the improvement rates in
ubjective symptoms and objective signs as judged by
he attending physicians. The efﬁcacy rate of ‘‘slightly
mproved’’ or better was 100% in the nifedipine CR group
nd 50% in the benidipine group. The former rate was sig-
iﬁcantly better (P = 0.001, chi-squared test).
In the Holter ECG ﬁndings, no ischemic ST changes could
e detected in any patients during the treatment period and
valuation was impossible.
Benidipine (n = 14)
value* Baseline 8 weeks P-value* P-value**
0002 1.41± 1.07 0.60± 0.80 0.1484 0.0146
2188 0.66± 1.12 0.25± 0.63 0.4375 0.8994
None None — —
016 10 0 <0.001 1.000
2834 203.2± 34.9 180.8± 22.3 0.8937 0.9511
1000 0.9± 0.2 0.9± 0.3 0.8054 0.2461
s.
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Figure 4 Changes in blood pressure.
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ropouts
mong the 28 patients subject to evaluation, four dropped
ut after 4 weeks because of insufﬁcient efﬁcacy and dis-
ontinued administration of the allocated test drug. These
our dropouts can be summarized as follows.
Case 1: 41-year-old man who smoked and had severe
hest pains twice a week. Treatment was started at
mg/day of benidipine, but since the number of attacks of
evere chest pain increased after 4 weeks, he was switched
o nifedipine CR at 40mg/day and the attacks disappeared.
Case 2: 57-year-old man who smoked and had moder-
te chest pains twice a week on average. Treatment was
tarted at 8mg/day of benidipine, but from the next day,
e had 14 chest pain attacks over a period of 4 weeks. When
e was changed to nifedipine CR at 40mg/day, the symp-
oms disappeared. He had hypertension (160/80mmHg), but
is blood pressure dropped to 140/78mmHg after treatment
ith benidipine. At one month after the switch to nifedipine
R, his blood pressure had dropped to 116/68mmHg and his
eart rate did not increase.
Case 3: 53-year-old man who smoked and had moder-
te to severe chest pains and palpitations three times a
eek. Treatment was started at 8mg/day of benidipine, but
ince chest pains and palpitations on effort remained after
t
q
o
f
sct judged by the attending physician.
weeks, he was changed to nifedipine CR at 40mg/day and
he symptoms disappeared.
Case 4: 62-year-old man who smoked and had severe
hest pain three or four times a week. Treatment was
tarted at 8mg/day of benidipine, but since mild chest pains
emained after 4 weeks, he was switched to nifedipine CR
t 40mg/day and the symptoms were alleviated.
iscussion
oronary spastic angina is angina pectoris caused by myocar-
ial ischemia due to transient excessive contractions. The
isease is characterized by a diurnal rhythm of attacks. The
ttacks appear when at rest from night through the early
orning and are unlikely to appear when working during the
ay [26]. The long-term prognosis of these patients has been
eported as comparatively good with the administration of
a channel blockers [27], but there are cases where sud-
en death or myocardial infarctions occur at times when
he coronary vasospasm activity is high as in cases of fre-
uent attacks or in the initial stage of treatment, and careful
bservation of the course is needed. Sueda et al. [13] per-
ormed a retrospective survey on 161 patients with coronary
pastic angina and showed that control of the number of
a
a
w
t
3
t
a
i
N
t
N
b
t
w
h
o
n
3
t
a
r
p
e
a
5
t
t
o
o
i
N
w
d
n
a
d
a
S
c
t
w
a
i
o
H
I
m
e
a
1
f
S
i
c
a
cEfﬁcacy of nifedipine CR for vasospastic angina
attacks of chest pain is important in improving the prognosis.
In a report by Yasue et al. [26] many myocardial infarctions
or sudden deaths occurred within three months after onset
in a 10-year observation of the course of patients with vari-
ant angina pectoris, but the prognosis of the patients was
good thereafter. Although the present study was short, only
8 weeks, the inhibitory effects on attacks were higher when
nifedipine CR at 40mg was given at night than when beni-
dipine at 4mg twice a day was administered to patients
with coronary spastic angina with frequent attacks. In some
patients, attacks disappeared when they discontinued beni-
dipine treatment and switched to nifedipine CR. The reason
for this was considered to be as follows. A clinical trial
on patients with variant angina during the development of
nifedipine CR was performed based on a dosing protocol in
accordance with the most common time periods for attacks
[23]. We consider that setting the administration time for
nifedipine at night for patients with coronary spastic angina
with attacks usually occurring in the early morning was ben-
eﬁcial in this study.
In pharmacological research, the dihydropyridine Ca
antagonist nifedipine has been shown to have coronary blood
ﬂow increasing action [28] and potent antispasmodic action
[29,30]. However, the prototype nifedipine product had a
short half-life in the blood [31] and a drug with contin-
uing effects on inhibition of ischemic attacks over a long
period was needed. Thereafter, nifedipine CR tablets with
effective blood levels maintained for 24 h at one dose a day
were developed in 1998 [18] following a nifedipine long-
acting tablet administered twice a day [32]. Nifedipine has
effective antihypertensive action at a plasma concentra-
tion of 12 ng/mL in hypertensive patients, but in studies
on angina pectoris, cases in which attacks could not be
inhibited unless higher concentrations were maintained in
accordance with severity were reported [33]. Therefore,
it is important to maintain higher concentrations in the
early morning in patients with coronary spastic angina with
frequent attacks in the early morning. Nifedipine CR was
effective in maintaining higher effective blood concentra-
tions for more than 12 h when the administration timing was
changed to after the evening meal. However, benidipine, a
dihydropyridine Ca channel blocker, the same as nifedipine,
has been reported to have coronary dilatation action and
sustained action better than those of nifedipine in phar-
macological research using various ischemic heart disease
models [34,35]. The approved dosage and administration of
benidipine for angina pectoris is 4mg twice a day [22]. In a
clinical study on patients with variant angina pectoris during
development, two doses of 8mg or 16mg/day were set. At a
dose of 16mg/day, ischemic attacks were signiﬁcantly inhib-
ited but at 8mg/day, inhibition of ischemic attacks was not
sufﬁcient [24]. Therefore, at the doses used in this study, the
potent spastic inhibitory effects of benidipine itself were not
sufﬁcient and especially in patients with relatively severe
angina with frequent attacks, it is possible that the short-
term therapeutic effects could not be achieved. Benidipine
has been reported to be involved in inhibition of the progres-
sion of arteriosclerosis due to endothelial injury, promotion
of oxidative stress, and rho/rho-kinase system activation
[36—39]. However, in the nifedipine CR group, the more
marked effects were observed after 8 weeks than after 4
weeks. Yui et al. [40] reported inhibition of worsening of
t
a
o
e245
ngina pectoris and inhibition of progression of coronary
rteriosclerosis after myocardial infarction when patients
ith a history of myocardial infarction were treated with
wice-daily sustained action nifedipine over a long period of
years. In a study by Pristipino et al. [41], it was reported
hat the incidence of coronary vasospasms in related sites
fter myocardial infarction in Japanese was higher than that
n Westerners. Nifedipine has also been reported to have
O production increasing action [42], more potent reduc-
ion of oxidative stress, and inhibition of the activity of
F-B via inﬂammation than other dihydropyridine agents in
asic and clinical research [43,44]. In the present therapeu-
ic results, nifedipine CR showed marked effects in patients
ho were dropouts for benidipine. In patients with essential
ypertension at SBP≥ 160mmHg, marked inhibitory effects
ccurred; SBP was less than 130mmHg within 4 weeks and
o increases in heart rate occurred. In our study, about
0% of patients had hypertension as a complication, but
hey were already under treatment with antihypertensive
gents and the mean blood pressure was within the normal
ange. Except in one patient with an excessive drop in blood
ressure on initial treatment with nifedipine CR, almost no
ffect on normal blood pressure values were observed after
dministration of nifedipine CR and benidipine. Although
7% of the enrolled patients were smokers, they were all told
o stop smoking when a deﬁnitive diagnosis of coronary spas-
ic angina was made and no patients smoked after initiation
f the study. The effect of stopping smoking on inhibition
f attacks was not studied, but no bias appeared to occur
n a comparison of two drugs under the same conditions.
o smoking in all patients in both groups simultaneously
ith the initiation of treatment with Ca antagonist and no
eterioration in their total cholesterol and serum creati-
ine levels might also be effective for prevention of CSA
ttacks.
In terms of the limitations of this study, the study was ran-
omized but was not blinded and bias in treatment by the
ttending physicians could not be ruled out. No ischemic
T segment changes were detected in Holter ECG and a
omparison of prevention of asymptomatic attacks between
he two groups was not possible. Since no washout period
as provided for ethical reasons in this research, it was
ssumed that it would be difﬁcult to detect ischemic ﬁnd-
ngs in the Holter ECG. Yasue et al. [26] reported that 60%
f ischemic attacks were asymptomatic in observation of
olter ECGs in 71 patients with coronary spastic angina.
n our research, we probably cannot say for sure if treat-
ent was complete or not because we were unable to
xamine asymptomatic attacks. It has been reported that
symptomatic ischemic ﬁndings completely disappeared in
5 patients who underwent Holter ECG examinations per-
ormed during development phase of nifedipine CR [23].
ince subjective symptoms and objective signs were mon-
tored by symptom diaries in our patients, there were no
lear evaluation criteria for severity and improvement of
ttacks and objectivity is difﬁcult to achieve under such
ircumstances.The involvement of coronary vasospasms is characteris-
ic of Japanese patients with ischemic heart disease [41],
nd large-scale clinical studies on differences in the effects
f inhibition of coronary vasospasms by Ca channel block-
rs should be performed in Japan. It is necessary to make
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valuations using stricter criteria and perform long-term
andomized comparative studies on Ca channel blockers in
he future.
onclusions
a channel blockers are recommended as drugs to treat
oronary spastic angina. We found that administration of
ifedipine CR at 40mg once a day after the evening meal in
nitial treatment of our patients showed inhibitory effects
n symptomatic attacks when compared with benidipine at
mg twice a day (after morning and evening meals). Nifedip-
ne CR may be useful in treatment from early morning of
atients with frequent attacks.
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